Artivabio
San Diego, US · Founded 2019 · 5 known investors
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
Founders & leadership
JB
Jennifer BushinChief Operating Officer
TJ
Thomas J. FarrellExecutive
FA
Fred AslaninPresident and Chief Executive Officer
JL
Jason LitteninChief Medical Officer2019–2022
EV
Esther van den BoomExecutive
PF
Peter FlynninCofounder & Strategic Advisor
Board
YH
Yong-Jun HuhBoard director
YH
Yu-Kyeong HwangBoard director
BK
Bong KohBoard director
LS
BD
YY
Yvonne YamanakaBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$163.4M disclosed across 2 rounds · 2020–2021
▶$120MraisedApr 2021 · 27 investors · BiotechnologyRule 506(b)
▶$120MraisedApr 2021 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer BushExecutive Officer
- Yong-Jun HuhDirector
- Thomas J. FarrellExecutive Officer
- Yu-Kyeong HwangDirector
- Fred AslanExecutive Officer, Director
- Jason LittenExecutive Officer
- Esther van den BoomExecutive Officer
- Bong KohDirector
- Laura StoppelDirector
- Brian DanielsDirector
- Peter FlynnExecutive Officer
- Yvonne YamanakaDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$43.4MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
▶$43.4MraisedJul 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yu-Kyeong HwangDirector
- Yvonne YamanakaDirector
- Laura StoppelDirector
- Jason LittenExecutive Officer
- Peter FlynnExecutive Officer
- Esther van den BoomExecutive Officer
- Brian DanielsDirector
- Yong-Jun HuhDirector
- Thomas J. FarrellExecutive Officer, Director
- Offering amount
- $78.4M
- Amount sold
- $43.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Artivabio do?
- Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
- Who are Artivabio's investors?
- Artivabio's investors include 5AM Ventures, EcoR1 Capital, RA Capital, venBio Partners, venBio Global Strategic.
- How much funding has Artivabio raised?
- Artivabio has disclosed $163.4M raised across 2 rounds.
- Where is Artivabio headquartered?
- Artivabio is headquartered in San Diego, US.